23andMe Holding Co. (ME)
- GlobeNewswire
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presentedSOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe) announced that clinical data from the Phase 1 portion of the Phase 1/2a study of 23ME-00610 has been selected for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida, Apri
- Motley Fool
AI Revolution on the Horizon: 2 High-Potential Growth Stocks to Watch in 2023
Artificial intelligence (AI) is all the rage these days, and given how rapidly the field is advancing, it's probably going to keep being the rage for quite some time -- potentially forever, if the evangelists are to be believed! While it's a bit tough to predict exactly what changes AI tools will bring about in our society, there are already quite a few businesses that are poised to benefit tremendously, and you've probably heard of some of them already. Let's examine two such companies to see how AI could power their future returns and help them compete.
- GlobeNewswire
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
92 percent of doctors in the U.S. say genetics is an important part of a patient’s complete health picture66 percent of doctors say genetic testing could help lead to better outcomes for their patients75 percent of people in the US said they’d be more likely to follow their doctor’s advice if they knew their genetic profile was used to personalize their care SUNNYVALE, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- A large percentage of people and doctors in the US say that using genetic testing cou
